| Literature DB >> 24967229 |
Driss Elkabbaj1, Abdelali Bahadi1, Yahia Cherrah2, Mourad Errasfa3, Rachid Eljaoudi2.
Abstract
The aim of this study was to evaluate the levels of malondialdehyde as an oxidative stress marker in the same hemodialysis patients after changing the quality of dialysate with ultrapure dialysis fluid. Methods. This prospective study concerns hemodialysis patients; all patients were in the first step treated with conventional dialysate, and in the second step (three months later) the same patients were treated with online produced ultrapure dialysis fluid. The malondialdehyde, C-reactive protein, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, fibrinogen, and albumin were quantified before the two steps. Results. Thirty-seven patients completed the study. Ultrapure dialysis fluid reduced but not significantly the malondialdehyde concentrations. Both dialysis fluids were associated with improvement in the malondialdehyde level before and after the hemodialysis session. In lipid parameters, there was a significant decrease with conventional dialysis fluid versus ultrapure dialysis fluid of triglycerides, total cholesterol, and high-density lipoprotein in patients' blood. Instead, the level of low-density lipoprotein, fibrinogen, albumin, and C-reactive protein does not change significantly. Conclusion. The lipid parameters were improved for triglycerides and total cholesterol. Malondialdehyde increases following the hemodialysis session, and the conventional dialysate increased malondialdehyde levels more than the ultrapure dialysis but the differences were not statistically significant.Entities:
Year: 2012 PMID: 24967229 PMCID: PMC4045418 DOI: 10.5402/2013/717849
Source DB: PubMed Journal: ISRN Nephrol ISSN: 2314-405X
Figure 1MDA calibration curve.
Characteristics of patients.
| Variable | Value |
|---|---|
| Age (years) m ± sd | 50.7 ± 16.5 |
| Sex ratio | 19/18 (male/female) |
| Initial nephropathy: | |
| Undetermined nephropathy | 15 (38) |
| Tubulointerstitial nephropathy | 8 (22) |
| Diabetic | 6 (16) |
| Glomerular nephropathy | 6 (16) |
| Amyloidosis | 1 (3) |
| Myeloma | 1 (3) |
| Duration in hemodialysis (months) median | 36 (16.5–106) |
| Body mass index (Kg/m2) m ± sd | 23.3 ± 3.4 |
| Single pool | 1.5 ± 0.19 |
Microbiological parameters of dialysis fluids in the two water treatments.
| Determination | Higher standards or limits (9.22) | Conventional dialysate | Ultrapure dialysate |
|---|---|---|---|
| Total germs—departure HD buckles (CFU/mL) | 100 | 10 | 7 |
| Total germs—return HD buckles (CFU/mL) | 100 | 20 | 9 |
| Endotoxin departure HD buckles (EU/mL) | 0.03 | 0.01 | <0.005 |
| Endotoxin return HD buckles (EU/mL) | 0.03 | 0.10 | <0.005 |
Blood lipids and other parameters before and after switching from conventional to ultrapure dialysis fluid.
| Variable | Conventional dialysis fluid | Ultrapure dialysis fluid |
|
|---|---|---|---|
| Triglycerides (mg/L) | 1.38 ± 0.62 | 1.13 ± 0.37 | 0.006* |
| Cholesterol (mg/L) | 1.72 ± 0.44 | 1.38 ± 0.13 | 0.001* |
| LDL (mg/L) | 1.01 ± 0.36 | 0.98 ± 0.30 | 0.6 |
| HDL (mg/L) | 0.39 ± 0.10 | 0.32 ± 0.12 | 0.02* |
| Fibrinogen (mg/L) | 4.1 ± 0.86 | 4.0 ± 1.0 | 0.6 |
| Albumin (g/L) | 35.9 ± 2.3 | 35.0 ± 4.0 | 0.2 |
| CRP (mg/L) | 2.5 (0.15–7.2) | 1.8 (0.1–7.4) | 0.3 |
*Statistically significant.
The values of MDA before and after hemodialysis session.
| MDA ( | MDA ( |
| |
|---|---|---|---|
| Conventional dialysate | 8.6 ± 1.5 | 13.0 ± 6.5 | <0.001* |
| Ultrapure dialysate | 7.9 ± 1.8 | 10.9 ± 3.5 | <0.001* |
*Statistically significant.
The values of MDA before and after and MDA difference in conventional dialysate and ultrapure dialysate fluid.
| Conventional dialysate | Ultrapure dialysate |
| |
|---|---|---|---|
| MDA1 ( | 8.6 ± 1.5 | 7.9 ± 1.8 | 0.12 |
| MDA2 ( | 13.0 ± 6.5 | 10.9 ± 3.5 | 0.10 |
| MDA difference (MDA2-MDA1) | 4.6 ± 6.4 | 2.9 ± 2.9 | 0.2 |